Adynxx Inc (ADYX)

0.00 USD  |  OTCM  |  Apr 25, 16:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap 0.00
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio --
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) 100.00%

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
URL http://www.adynxx.com
Investor Relations URL http://ir.stockpr.com/alliqua/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Nov. 04, 2016
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 06, 2019

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
URL http://www.adynxx.com
Investor Relations URL http://ir.stockpr.com/alliqua/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Nov. 04, 2016
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 06, 2019